HealthQuill Microglia
Sanofi SA will acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, for $470 million.
Drugs Health Pharma

France’s Sanofi SA to acquire US-based Vigil Neuroscience for $470 million 

HQ Team May 22, 2025: Sanofi SA will acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies.

Read More
US adults who will develop dementia every year will rise to one million in 2060 from 514,000 in 2020, according to a study published in Nature Medicine.
Health

Semaglutide may combat Alzheimer’s by reducing brain inflammation:Study

HQ Team March 21, 2025: A study from China adds to mounting evidence that semaglutide—a medication widely used for type 2 diabetes (Ozempic).

Read More
A blood protein, called fibrin, which supports clotting, is responsible for switching on detrimental genes in Alzheimer’s disease and multiple sclerosis, researchers say.
Drugs Health Pharma

Alzheimer’s develops when hero microglia turns into a villain in brain

HQ Team June 11, 2023: A blood protein, called fibrin, which supports clotting, is responsible for switching on detrimental genes in Alzheimer’s disease.

Read More